中枢神経系治療学の世界市場

中枢神経系治療学の世界市場は2030年までに1,565億米ドルに到達

2024年に1,070億米ドルと推定される中枢神経系治療学の世界市場は、2024年から2030年にかけてCAGR 6.5%で成長し、2030年には1,565億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである鎮痛薬は、CAGR 8.6%を記録し、分析期間終了時には466億米ドルに達すると予測されます。抗コリン薬セグメントの成長率は、分析期間中CAGR 4.6%と推定されます。

米国市場は292億米ドルと推定、中国はCAGR 10.6％で成長予測

米国の中枢神経系治療学市場は2024年に292億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに329億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは10.6%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.1%と6.5%と予測されています。欧州では、ドイツがCAGR 4.3%で成長すると予測されています。

世界の中枢神経系治療学市場- 主要動向と促進要因のまとめ

中枢神経系治療学が慢性疾患管理と神経イノベーションの焦点となる理由とは？

中枢神経系（CNS）治療薬は、アルツハイマー病、パーキンソン病、てんかん、多発性硬化症、うつ病、不安神経症、統合失調症など、幅広い神経・精神疾患への対応において極めて重要です。人口の高齢化、ライフスタイルの変化、メンタルヘルスに対する意識の高まりなどを背景に、中枢神経系疾患の世界の有病率は着実に上昇しており、神経化学的不均衡、神経炎症、神経変性経路を効果的に標的とする治療法の開発が重視されるようになっています。中枢神経系治療薬は、慢性および急性の神経疾患における症状管理および疾患改善戦略の双方において、依然として不可欠です。

中枢神経系医薬品の開発には、血液脳関門通過の問題、臨床試験の複雑さ、高い失敗率といった歴史的課題があるにもかかわらず、神経生物学、バイオマーカー、デジタル評価項目の進歩により、パイプラインの革新が活性化しています。神経学的健康が公衆衛生の最優先課題となるにつれ、中枢神経系治療薬は医薬品研究開発および世界な保健政策課題の最前線に躍り出ようとしています。

メカニズムに基づくターゲティング、生物学的製剤、デジタルセラピューティクスは、次世代の中枢神経系治療をどのように形成するのか？

中枢神経系領域における医薬品開発は、神経伝達物質の調節（ドーパミン、セロトニン、GABAなど）、受容体拮抗作用、アルツハイマー病におけるアミロイドβやタウのターゲティングなどの疾患修飾メカニズムに焦点を当てた、メカニズム特異的なアプローチによってますます推進されています。モノクローナル抗体、神経栄養因子、遺伝子治療などの生物学的製剤は、特に従来の低分子製剤では有効性が限られていた治療抵抗性の神経変性疾患において支持を集めています。

これと並行して、モバイル認知行動療法（CBT）アプリ、経頭蓋磁気刺激（TMS）、バーチャルリアリティ（VR）支援神経リハビリテーションなどのデジタル治療薬や神経技術プラットフォームが、治療のツールボックスを拡大し、補助的かつ非薬物的な選択肢を提供しています。コンパニオン診断、デジタルバイオマーカー、AIを活用した臨床試験募集ツールは、医薬品開発のタイムラインをさらに加速させ、臨床試験における患者の層別化を改善し、有効性評価と規制上の成功における長年の課題に対処しています。

CNS治療薬の需要が伸びている地域と市場拡大を牽引している適応症は？

北米は世界の中枢神経系治療薬市場を独占しており、その背景には高い疾患有病率、高度なヘルスケアインフラ、神経学的研究開発への旺盛な投資があります。特に米国は、新薬の上市、臨床試験の活発化、先進的な治療法の採用でリードし続けています。欧州は、脳の健康、心の健康、神経変性疾患プログラムへの積極的な取り組みでこれに続いています。アジア太平洋地域は、日本、中国、韓国などの国々で、メンタルヘルスに対する意識の高まり、高齢化社会の拡大、診断や専門医療へのアクセスの改善などが後押しし、成長のホットスポットとして浮上しています。

主要な治療分野には、神経変性疾患（アルツハイマー病、パーキンソン病）、精神疾患（うつ病、双極性障害、統合失調症）、発作関連疾患（てんかん）などがあります。さらに、希少な小児中枢神経系疾患、神経因性疼痛、外傷性脳損傷（TBI）などの新たな適応症が、臨床的・商業的関心を牽引しています。専門クリニック、神経センター、長期介護施設、デジタルメンタルヘルスプラットフォームはすべて、治療へのアクセスと市場成長に貢献しています。

中枢神経系治療学市場の世界的成長の原動力は？

世界の中枢神経系治療薬市場は、疾病負担の増加、精神・神経の健康に対する意識の高まり、治療科学の急速な進歩により成長しています。複数の中枢神経系疾患に対するアンメットニーズに加え、人口動態の圧力やヘルスケアのデジタル化が相まって、新規治療薬と改良型治療薬の両方に対する需要が持続的に高まっています。神経科学研究に対する官民の投資は、希少疾病用医薬品（オーファンドラッグ）開発や促進パスウェイに対する規制当局の支援とともに、技術革新をさらに後押ししています。

製薬企業は、買収や提携、AIを活用した創薬プラットフォームを通じて、中枢神経系をターゲットとするパイプラインを拡充しています。同時に、患者アドボカシー、デジタルケアモデル、個別化治療パラダイムは、業界をより総合的でアウトカム重視のアプローチへとシフトさせています。中枢神経系治療における複雑性が深まり、精密治療が実現可能になるにつれ、市場の将来を形作る決定的な疑問が生じます。中枢神経系治療薬は、臨床上の不確実性と世界のアクセシビリティという2つの課題に対処しながら、バイオマーカーを活用したイノベーション、分野横断的なケアモデル、拡張可能なデリバリープラットフォームを通じて進化し続けることができるのだろうか。

セグメント

薬剤クラス別（鎮痛薬、抗コリン薬、抗けいれん薬、鎮静薬・催眠薬、抗うつ薬、その他の薬剤クラス）、疾患タイプ別（神経変性疾患、メンタルヘルス、神経血管疾患、中枢神経系外傷、中枢神経系がん、その他の疾患タイプ）、流通チャネル別（病院薬局、小売薬局、オンライン薬局）

調査対象企業の例（注目の44社）

• AbbVie Inc.
• Allergan plc
• Anavex Life Sciences Corp.
• AstraZeneca plc
• Biogen Inc.
• Bristol Myers Squibb
• Cipla Limited
• Dr. Reddy's Laboratories Ltd.
• Eli Lilly and Company
• GlaxoSmithKline plc
• H. Lundbeck A/S
• Johnson & Johnson
• Lupin Limited
• Merck & Co., Inc.
• Novartis AG
• Otsuka Pharmaceutical Co., Ltd.
• Pfizer Inc.
• Roche Holding AG
• Takeda Pharmaceutical Company Ltd.
• Teva Pharmaceutical Industries Ltd.

関税影響係数

Global Industry Analystsは、本社国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・業界団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Central Nervous System Therapeutics Market to Reach US$156.5 Billion by 2030

The global market for Central Nervous System Therapeutics estimated at US$107.0 Billion in the year 2024, is expected to reach US$156.5 Billion by 2030, growing at a CAGR of 6.5% over the analysis period 2024-2030. Analgesics, one of the segments analyzed in the report, is expected to record a 8.6% CAGR and reach US$46.6 Billion by the end of the analysis period. Growth in the Anti-Cholinergic Agents segment is estimated at 4.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$29.2 Billion While China is Forecast to Grow at 10.6% CAGR

The Central Nervous System Therapeutics market in the U.S. is estimated at US$29.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$32.9 Billion by the year 2030 trailing a CAGR of 10.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.1% and 6.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.3% CAGR.

Global Central Nervous System Therapeutics Market - Key Trends & Drivers Summarized

Why Are Central Nervous System Therapeutics a Focal Point in Chronic Disease Management and Neurological Innovation?

Central nervous system (CNS) therapeutics are pivotal in addressing a broad range of neurological and psychiatric disorders, including Alzheimer’s disease, Parkinson’s disease, epilepsy, multiple sclerosis, depression, anxiety, and schizophrenia. With the global prevalence of CNS disorders steadily rising-fueled by aging populations, lifestyle shifts, and increased mental health awareness-there is a growing emphasis on developing therapies that can effectively target neurochemical imbalances, neuroinflammation, and neurodegenerative pathways. CNS drugs remain indispensable in both symptom management and disease modification strategies across chronic and acute neurological conditions.

Despite historical challenges in CNS drug development-stemming from blood-brain barrier penetration issues, clinical trial complexity, and high failure rates-advances in neurobiology, biomarkers, and digital endpoints are revitalizing pipeline innovation. As neurological health becomes a top public health priority, CNS therapeutics are moving to the forefront of pharmaceutical R&D and global health policy agendas.

How Are Mechanism-Based Targeting, Biologics, and Digital Therapeutics Shaping the Next Generation of CNS Treatments?

Drug development in the CNS space is increasingly driven by mechanism-specific approaches, focusing on neurotransmitter modulation (e.g., dopamine, serotonin, GABA), receptor antagonism, and disease-modifying mechanisms such as amyloid-beta and tau targeting in Alzheimer’s disease. Biologics-including monoclonal antibodies, neurotrophic factors, and gene therapies-are gaining traction, particularly in treatment-resistant neurodegenerative diseases where traditional small molecules have shown limited efficacy.

In parallel, digital therapeutics and neurotechnology platforms-such as mobile cognitive behavioral therapy (CBT) apps, transcranial magnetic stimulation (TMS), and virtual reality (VR)-assisted neurorehabilitation-are expanding the therapeutic toolbox, offering adjunctive and non-pharmacologic options. Companion diagnostics, digital biomarkers, and AI-powered trial recruitment tools are further accelerating drug development timelines and improving patient stratification in clinical trials, addressing longstanding challenges in efficacy assessment and regulatory success.

Where Is Demand for CNS Therapeutics Growing and Which Indications Are Driving Market Expansion?

North America dominates the global CNS therapeutics market, driven by high disease prevalence, advanced healthcare infrastructure, and strong investment in neurological R&D. The U.S., in particular, continues to lead in new drug launches, clinical trial activity, and adoption of advanced treatment modalities. Europe follows with active initiatives in brain health, mental wellness, and neurodegenerative disease programs. Asia-Pacific is emerging as a growth hotspot, fueled by rising mental health awareness, expanding aging populations, and improved access to diagnostics and specialty care in countries such as Japan, China, and South Korea.

Leading therapeutic segments include neurodegenerative disorders (Alzheimer’s, Parkinson’s), psychiatric conditions (depression, bipolar disorder, schizophrenia), and seizure-related diseases (epilepsy). Additionally, emerging indications such as rare pediatric CNS diseases, neuropathic pain, and traumatic brain injury (TBI) are driving clinical and commercial interest. Specialty clinics, neurology centers, long-term care facilities, and digital mental health platforms are all contributing to treatment access and market growth.

What Is Fueling the Global Growth of the Central Nervous System Therapeutics Market?

The global CNS therapeutics market is growing due to increasing disease burden, heightened awareness of mental and neurological health, and the rapid advancement of therapeutic science. Unmet needs across multiple CNS indications, combined with demographic pressures and healthcare digitization, are generating sustained demand for both novel and reformulated therapies. Public and private sector investments in neuroscience research, along with regulatory support for orphan drug development and accelerated pathways, are further incentivizing innovation.

Pharmaceutical companies are expanding pipelines through acquisitions, collaborations, and AI-enabled drug discovery platforms focused on CNS targets. At the same time, patient advocacy, digital care models, and personalized treatment paradigms are shifting the industry toward more holistic, outcomes-driven approaches. As complexity in CNS care deepens and precision treatment becomes more attainable, a defining question shapes the market’s future: Can CNS therapeutics continue to evolve through biomarker-guided innovation, cross-disciplinary care models, and scalable delivery platforms-while addressing the dual challenge of clinical uncertainty and global accessibility?

SCOPE OF STUDY:

The report analyzes the Central Nervous System Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants, Other Drug Classes); Disease Type (Neurodegenerative Disorders, Mental Health, Neurovascular Diseases, CNS Trauma, CNS Cancer, Other Disease Types); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

• AbbVie Inc.
• Allergan plc
• Anavex Life Sciences Corp.
• AstraZeneca plc
• Biogen Inc.
• Bristol Myers Squibb
• Cipla Limited
• Dr. Reddy's Laboratories Ltd.
• Eli Lilly and Company
• GlaxoSmithKline plc
• H. Lundbeck A/S
• Johnson & Johnson
• Lupin Limited
• Merck & Co., Inc.
• Novartis AG
• Otsuka Pharmaceutical Co., Ltd.
• Pfizer Inc.
• Roche Holding AG
• Takeda Pharmaceutical Company Ltd.
• Teva Pharmaceutical Industries Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Central Nervous System Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Prevalence of Alzheimers, Parkinsons, and Epilepsy Fuels Demand for CNS Drug Innovation
  • Biologics, Gene Therapies, and Small Molecules Converge in Development Pipelines for CNS Disorders
  • Cross-BBB Delivery Technologies and Neurotargeted Carriers Address Long-Standing Bioavailability Barriers
  • Psychiatric Disorders Like Depression and Bipolar Drive Growth in Multimodal CNS Treatment Strategies
  • Digital Therapeutics and CNS Drug Monitoring Tools Expand Clinical Management Capabilities
  • Patient-Centered Outcome Measures Gain Priority in CNS Trial Designs and Payer Decisions
  • High Unmet Need in Rare Neurological Conditions Spurs Orphan Drug Development Activity
  • Aging Demographics and Lifestyle Shifts Expand CNS Therapeutic Demand Across Regions
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Central Nervous System Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Central Nervous System Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Central Nervous System Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Analgesics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Analgesics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Analgesics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Anti-Cholinergic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Anti-Cholinergic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Anti-Cholinergic Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Anticonvulsants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Anticonvulsants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Anticonvulsants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Sedatives & Hypnotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Sedatives & Hypnotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Sedatives & Hypnotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Anti-Depressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Anti-Depressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Anti-Depressants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for CNS Trauma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for CNS Trauma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for CNS Trauma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for CNS Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for CNS Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for CNS Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Neurodegenerative Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Neurodegenerative Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Neurodegenerative Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Mental Health by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Mental Health by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Mental Health by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Neurovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Neurovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Neurovascular Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 47: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 48: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Central Nervous System Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 50: USA Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Drug Class - Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: USA Historic Review for Central Nervous System Therapeutics by Drug Class - Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: USA 15-Year Perspective for Central Nervous System Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 53: USA Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Disease Type - CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: USA Historic Review for Central Nervous System Therapeutics by Disease Type - CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: USA 15-Year Perspective for Central Nervous System Therapeutics by Disease Type - Percentage Breakdown of Value Sales for CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases for the Years 2015, 2025 & 2030
  • TABLE 56: USA Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: USA Historic Review for Central Nervous System Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: USA 15-Year Perspective for Central Nervous System Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 59: Canada Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Drug Class - Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Canada Historic Review for Central Nervous System Therapeutics by Drug Class - Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Canada 15-Year Perspective for Central Nervous System Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 62: Canada Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Disease Type - CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Canada Historic Review for Central Nervous System Therapeutics by Disease Type - CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Canada 15-Year Perspective for Central Nervous System Therapeutics by Disease Type - Percentage Breakdown of Value Sales for CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases for the Years 2015, 2025 & 2030
  • TABLE 65: Canada Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Canada Historic Review for Central Nervous System Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Canada 15-Year Perspective for Central Nervous System Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• JAPAN
  • Central Nervous System Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 68: Japan Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Drug Class - Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Japan Historic Review for Central Nervous System Therapeutics by Drug Class - Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: Japan 15-Year Perspective for Central Nervous System Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 71: Japan Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Disease Type - CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Japan Historic Review for Central Nervous System Therapeutics by Disease Type - CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Japan 15-Year Perspective for Central Nervous System Therapeutics by Disease Type - Percentage Breakdown of Value Sales for CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases for the Years 2015, 2025 & 2030
  • TABLE 74: Japan Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Japan Historic Review for Central Nervous System Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Japan 15-Year Perspective for Central Nervous System Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• CHINA
  • Central Nervous System Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 77: China Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Drug Class - Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: China Historic Review for Central Nervous System Therapeutics by Drug Class - Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: China 15-Year Perspective for Central Nervous System Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 80: China Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Disease Type - CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: China Historic Review for Central Nervous System Therapeutics by Disease Type - CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: China 15-Year Perspective for Central Nervous System Therapeutics by Disease Type - Percentage Breakdown of Value Sales for CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases for the Years 2015, 2025 & 2030
  • TABLE 83: China Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: China Historic Review for Central Nervous System Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: China 15-Year Perspective for Central Nervous System Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• EUROPE
  • Central Nervous System Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 86: Europe Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 87: Europe Historic Review for Central Nervous System Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Europe 15-Year Perspective for Central Nervous System Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 89: Europe Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Drug Class - Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Europe Historic Review for Central Nervous System Therapeutics by Drug Class - Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: Europe 15-Year Perspective for Central Nervous System Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 92: Europe Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Disease Type - CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Europe Historic Review for Central Nervous System Therapeutics by Disease Type - CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Europe 15-Year Perspective for Central Nervous System Therapeutics by Disease Type - Percentage Breakdown of Value Sales for CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases for the Years 2015, 2025 & 2030
  • TABLE 95: Europe Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Europe Historic Review for Central Nervous System Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Europe 15-Year Perspective for Central Nervous System Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• FRANCE
  • Central Nervous System Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 98: France Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Drug Class - Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: France Historic Review for Central Nervous System Therapeutics by Drug Class - Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: France 15-Year Perspective for Central Nervous System Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 101: France Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Disease Type - CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: France Historic Review for Central Nervous System Therapeutics by Disease Type - CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: France 15-Year Perspective for Central Nervous System Therapeutics by Disease Type - Percentage Breakdown of Value Sales for CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases for the Years 2015, 2025 & 2030
  • TABLE 104: France Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: France Historic Review for Central Nervous System Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: France 15-Year Perspective for Central Nervous System Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• GERMANY
  • Central Nervous System Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 107: Germany Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Drug Class - Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Germany Historic Review for Central Nervous System Therapeutics by Drug Class - Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Germany 15-Year Perspective for Central Nervous System Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 110: Germany Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Disease Type - CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Germany Historic Review for Central Nervous System Therapeutics by Disease Type - CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Germany 15-Year Perspective for Central Nervous System Therapeutics by Disease Type - Percentage Breakdown of Value Sales for CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases for the Years 2015, 2025 & 2030
  • TABLE 113: Germany Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Germany Historic Review for Central Nervous System Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Germany 15-Year Perspective for Central Nervous System Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 116: Italy Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Drug Class - Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Italy Historic Review for Central Nervous System Therapeutics by Drug Class - Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: Italy 15-Year Perspective for Central Nervous System Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 119: Italy Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Disease Type - CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Italy Historic Review for Central Nervous System Therapeutics by Disease Type - CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Italy 15-Year Perspective for Central Nervous System Therapeutics by Disease Type - Percentage Breakdown of Value Sales for CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases for the Years 2015, 2025 & 2030
  • TABLE 122: Italy Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Italy Historic Review for Central Nervous System Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Italy 15-Year Perspective for Central Nervous System Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Central Nervous System Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 125: UK Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Drug Class - Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: UK Historic Review for Central Nervous System Therapeutics by Drug Class - Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: UK 15-Year Perspective for Central Nervous System Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 128: UK Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Disease Type - CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: UK Historic Review for Central Nervous System Therapeutics by Disease Type - CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: UK 15-Year Perspective for Central Nervous System Therapeutics by Disease Type - Percentage Breakdown of Value Sales for CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases for the Years 2015, 2025 & 2030
  • TABLE 131: UK Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: UK Historic Review for Central Nervous System Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: UK 15-Year Perspective for Central Nervous System Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 134: Spain Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Drug Class - Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Spain Historic Review for Central Nervous System Therapeutics by Drug Class - Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Spain 15-Year Perspective for Central Nervous System Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 137: Spain Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Disease Type - CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Spain Historic Review for Central Nervous System Therapeutics by Disease Type - CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Spain 15-Year Perspective for Central Nervous System Therapeutics by Disease Type - Percentage Breakdown of Value Sales for CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases for the Years 2015, 2025 & 2030
  • TABLE 140: Spain Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Spain Historic Review for Central Nervous System Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Spain 15-Year Perspective for Central Nervous System Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 143: Russia Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Drug Class - Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Russia Historic Review for Central Nervous System Therapeutics by Drug Class - Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Russia 15-Year Perspective for Central Nervous System Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 146: Russia Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Disease Type - CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Russia Historic Review for Central Nervous System Therapeutics by Disease Type - CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Russia 15-Year Perspective for Central Nervous System Therapeutics by Disease Type - Percentage Breakdown of Value Sales for CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases for the Years 2015, 2025 & 2030
  • TABLE 149: Russia Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Russia Historic Review for Central Nervous System Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Russia 15-Year Perspective for Central Nervous System Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 152: Rest of Europe Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Drug Class - Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Rest of Europe Historic Review for Central Nervous System Therapeutics by Drug Class - Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Rest of Europe 15-Year Perspective for Central Nervous System Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 155: Rest of Europe Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Disease Type - CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Rest of Europe Historic Review for Central Nervous System Therapeutics by Disease Type - CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Rest of Europe 15-Year Perspective for Central Nervous System Therapeutics by Disease Type - Percentage Breakdown of Value Sales for CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases for the Years 2015, 2025 & 2030
  • TABLE 158: Rest of Europe Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Rest of Europe Historic Review for Central Nervous System Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Rest of Europe 15-Year Perspective for Central Nervous System Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Central Nervous System Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 162: Asia-Pacific Historic Review for Central Nervous System Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Asia-Pacific 15-Year Perspective for Central Nervous System Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Drug Class - Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Asia-Pacific Historic Review for Central Nervous System Therapeutics by Drug Class - Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Asia-Pacific 15-Year Perspective for Central Nervous System Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 167: Asia-Pacific Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Disease Type - CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Asia-Pacific Historic Review for Central Nervous System Therapeutics by Disease Type - CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Asia-Pacific 15-Year Perspective for Central Nervous System Therapeutics by Disease Type - Percentage Breakdown of Value Sales for CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases for the Years 2015, 2025 & 2030
  • TABLE 170: Asia-Pacific Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Asia-Pacific Historic Review for Central Nervous System Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Asia-Pacific 15-Year Perspective for Central Nervous System Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Central Nervous System Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 173: Australia Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Drug Class - Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Australia Historic Review for Central Nervous System Therapeutics by Drug Class - Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: Australia 15-Year Perspective for Central Nervous System Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 176: Australia Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Disease Type - CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Australia Historic Review for Central Nervous System Therapeutics by Disease Type - CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: Australia 15-Year Perspective for Central Nervous System Therapeutics by Disease Type - Percentage Breakdown of Value Sales for CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases for the Years 2015, 2025 & 2030
  • TABLE 179: Australia Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Australia Historic Review for Central Nervous System Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: Australia 15-Year Perspective for Central Nervous System Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• INDIA
  • Central Nervous System Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 182: India Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Drug Class - Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: India Historic Review for Central Nervous System Therapeutics by Drug Class - Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: India 15-Year Perspective for Central Nervous System Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 185: India Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Disease Type - CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: India Historic Review for Central Nervous System Therapeutics by Disease Type - CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: India 15-Year Perspective for Central Nervous System Therapeutics by Disease Type - Percentage Breakdown of Value Sales for CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases for the Years 2015, 2025 & 2030
  • TABLE 188: India Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: India Historic Review for Central Nervous System Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: India 15-Year Perspective for Central Nervous System Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 191: South Korea Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Drug Class - Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: South Korea Historic Review for Central Nervous System Therapeutics by Drug Class - Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: South Korea 15-Year Perspective for Central Nervous System Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 194: South Korea Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Disease Type - CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: South Korea Historic Review for Central Nervous System Therapeutics by Disease Type - CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: South Korea 15-Year Perspective for Central Nervous System Therapeutics by Disease Type - Percentage Breakdown of Value Sales for CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases for the Years 2015, 2025 & 2030
  • TABLE 197: South Korea Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: South Korea Historic Review for Central Nervous System Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: South Korea 15-Year Perspective for Central Nervous System Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 200: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Drug Class - Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Rest of Asia-Pacific Historic Review for Central Nervous System Therapeutics by Drug Class - Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Rest of Asia-Pacific 15-Year Perspective for Central Nervous System Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 203: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Disease Type - CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Rest of Asia-Pacific Historic Review for Central Nervous System Therapeutics by Disease Type - CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Rest of Asia-Pacific 15-Year Perspective for Central Nervous System Therapeutics by Disease Type - Percentage Breakdown of Value Sales for CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases for the Years 2015, 2025 & 2030
  • TABLE 206: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Rest of Asia-Pacific Historic Review for Central Nervous System Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Rest of Asia-Pacific 15-Year Perspective for Central Nervous System Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Central Nervous System Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 209: Latin America Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 210: Latin America Historic Review for Central Nervous System Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Latin America 15-Year Perspective for Central Nervous System Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 212: Latin America Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Drug Class - Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Latin America Historic Review for Central Nervous System Therapeutics by Drug Class - Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Latin America 15-Year Perspective for Central Nervous System Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 215: Latin America Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Disease Type - CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Latin America Historic Review for Central Nervous System Therapeutics by Disease Type - CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Latin America 15-Year Perspective for Central Nervous System Therapeutics by Disease Type - Percentage Breakdown of Value Sales for CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases for the Years 2015, 2025 & 2030
  • TABLE 218: Latin America Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Latin America Historic Review for Central Nervous System Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Latin America 15-Year Perspective for Central Nervous System Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 221: Argentina Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Drug Class - Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Argentina Historic Review for Central Nervous System Therapeutics by Drug Class - Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Argentina 15-Year Perspective for Central Nervous System Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 224: Argentina Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Disease Type - CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Argentina Historic Review for Central Nervous System Therapeutics by Disease Type - CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Argentina 15-Year Perspective for Central Nervous System Therapeutics by Disease Type - Percentage Breakdown of Value Sales for CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases for the Years 2015, 2025 & 2030
  • TABLE 227: Argentina Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Argentina Historic Review for Central Nervous System Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Argentina 15-Year Perspective for Central Nervous System Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 230: Brazil Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Drug Class - Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Brazil Historic Review for Central Nervous System Therapeutics by Drug Class - Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Brazil 15-Year Perspective for Central Nervous System Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 233: Brazil Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Disease Type - CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Brazil Historic Review for Central Nervous System Therapeutics by Disease Type - CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Brazil 15-Year Perspective for Central Nervous System Therapeutics by Disease Type - Percentage Breakdown of Value Sales for CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases for the Years 2015, 2025 & 2030
  • TABLE 236: Brazil Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Brazil Historic Review for Central Nervous System Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Brazil 15-Year Perspective for Central Nervous System Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 239: Mexico Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Drug Class - Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Mexico Historic Review for Central Nervous System Therapeutics by Drug Class - Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Mexico 15-Year Perspective for Central Nervous System Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 242: Mexico Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Disease Type - CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Mexico Historic Review for Central Nervous System Therapeutics by Disease Type - CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Mexico 15-Year Perspective for Central Nervous System Therapeutics by Disease Type - Percentage Breakdown of Value Sales for CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases for the Years 2015, 2025 & 2030
  • TABLE 245: Mexico Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Mexico Historic Review for Central Nervous System Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Mexico 15-Year Perspective for Central Nervous System Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 248: Rest of Latin America Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Drug Class - Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Rest of Latin America Historic Review for Central Nervous System Therapeutics by Drug Class - Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Rest of Latin America 15-Year Perspective for Central Nervous System Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 251: Rest of Latin America Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Disease Type - CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Rest of Latin America Historic Review for Central Nervous System Therapeutics by Disease Type - CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Rest of Latin America 15-Year Perspective for Central Nervous System Therapeutics by Disease Type - Percentage Breakdown of Value Sales for CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases for the Years 2015, 2025 & 2030
  • TABLE 254: Rest of Latin America Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Rest of Latin America Historic Review for Central Nervous System Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Rest of Latin America 15-Year Perspective for Central Nervous System Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Central Nervous System Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 257: Middle East Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 258: Middle East Historic Review for Central Nervous System Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Middle East 15-Year Perspective for Central Nervous System Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 260: Middle East Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Drug Class - Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Middle East Historic Review for Central Nervous System Therapeutics by Drug Class - Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Middle East 15-Year Perspective for Central Nervous System Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 263: Middle East Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Disease Type - CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Middle East Historic Review for Central Nervous System Therapeutics by Disease Type - CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Middle East 15-Year Perspective for Central Nervous System Therapeutics by Disease Type - Percentage Breakdown of Value Sales for CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases for the Years 2015, 2025 & 2030
  • TABLE 266: Middle East Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Middle East Historic Review for Central Nervous System Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Middle East 15-Year Perspective for Central Nervous System Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 269: Iran Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Drug Class - Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Iran Historic Review for Central Nervous System Therapeutics by Drug Class - Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Iran 15-Year Perspective for Central Nervous System Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 272: Iran Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Disease Type - CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Iran Historic Review for Central Nervous System Therapeutics by Disease Type - CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Iran 15-Year Perspective for Central Nervous System Therapeutics by Disease Type - Percentage Breakdown of Value Sales for CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases for the Years 2015, 2025 & 2030
  • TABLE 275: Iran Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Iran Historic Review for Central Nervous System Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Iran 15-Year Perspective for Central Nervous System Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 278: Israel Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Drug Class - Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Israel Historic Review for Central Nervous System Therapeutics by Drug Class - Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Israel 15-Year Perspective for Central Nervous System Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 281: Israel Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Disease Type - CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Israel Historic Review for Central Nervous System Therapeutics by Disease Type - CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Israel 15-Year Perspective for Central Nervous System Therapeutics by Disease Type - Percentage Breakdown of Value Sales for CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases for the Years 2015, 2025 & 2030
  • TABLE 284: Israel Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Israel Historic Review for Central Nervous System Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Israel 15-Year Perspective for Central Nervous System Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 287: Saudi Arabia Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Drug Class - Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Saudi Arabia Historic Review for Central Nervous System Therapeutics by Drug Class - Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: Saudi Arabia 15-Year Perspective for Central Nervous System Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 290: Saudi Arabia Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Disease Type - CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Saudi Arabia Historic Review for Central Nervous System Therapeutics by Disease Type - CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Saudi Arabia 15-Year Perspective for Central Nervous System Therapeutics by Disease Type - Percentage Breakdown of Value Sales for CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases for the Years 2015, 2025 & 2030
  • TABLE 293: Saudi Arabia Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Saudi Arabia Historic Review for Central Nervous System Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Saudi Arabia 15-Year Perspective for Central Nervous System Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 296: UAE Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Drug Class - Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: UAE Historic Review for Central Nervous System Therapeutics by Drug Class - Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: UAE 15-Year Perspective for Central Nervous System Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 299: UAE Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Disease Type - CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: UAE Historic Review for Central Nervous System Therapeutics by Disease Type - CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: UAE 15-Year Perspective for Central Nervous System Therapeutics by Disease Type - Percentage Breakdown of Value Sales for CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases for the Years 2015, 2025 & 2030
  • TABLE 302: UAE Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: UAE Historic Review for Central Nervous System Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: UAE 15-Year Perspective for Central Nervous System Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 305: Rest of Middle East Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Drug Class - Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Rest of Middle East Historic Review for Central Nervous System Therapeutics by Drug Class - Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Rest of Middle East 15-Year Perspective for Central Nervous System Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 308: Rest of Middle East Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Disease Type - CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Rest of Middle East Historic Review for Central Nervous System Therapeutics by Disease Type - CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Rest of Middle East 15-Year Perspective for Central Nervous System Therapeutics by Disease Type - Percentage Breakdown of Value Sales for CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases for the Years 2015, 2025 & 2030
  • TABLE 311: Rest of Middle East Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Rest of Middle East Historic Review for Central Nervous System Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 313: Rest of Middle East 15-Year Perspective for Central Nervous System Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• AFRICA
  • Central Nervous System Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 314: Africa Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Drug Class - Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Africa Historic Review for Central Nervous System Therapeutics by Drug Class - Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 316: Africa 15-Year Perspective for Central Nervous System Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 317: Africa Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Disease Type - CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Africa Historic Review for Central Nervous System Therapeutics by Disease Type - CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 319: Africa 15-Year Perspective for Central Nervous System Therapeutics by Disease Type - Percentage Breakdown of Value Sales for CNS Trauma, CNS Cancer, Other Disease Types, Neurodegenerative Disorders, Mental Health and Neurovascular Diseases for the Years 2015, 2025 & 2030
  • TABLE 320: Africa Recent Past, Current & Future Analysis for Central Nervous System Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Africa Historic Review for Central Nervous System Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 322: Africa 15-Year Perspective for Central Nervous System Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

IV. COMPETITION